Pre-order Enquiry
Request Free Sample
Global Zafirlukas Market Insights, Forecast to 2028
SKU ID : QYR-20154953 | Publishing Date : 08-Feb-2022 | No. of pages : 90
Request Sample
Request Customization
Check Discounts
Zafirlukast is an orally administered leukotriene receptor antagonist (LTRA) used for the chronic treatment of asthma. Zafirlukast (brand name Accolate) was the first cysteinyl leukotriene receptor antagonist approved in the United States. It is now approved in many other countries under other brand names
Market Analysis and Insights: Global Zafirlukas Market
Due to the COVID-19 pandemic, the global Zafirlukas market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 10mg accounting for % of the Zafirlukas global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Antiasthmatic Agent segment is altered to an % CAGR throughout this forecast period.
China Zafirlukas market size is valued at US$ million in 2021, while the US and Europe Zafirlukas are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Zafirlukas landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Zafirlukas include Astrazeneca, Par Pharm, Dr Reddys Labs, Medisure, Hamaz Pharma, Delta Pharma, Chiesi Farmaceutici and General Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Zafirlukas Scope and Segment
Zafirlukas market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Zafirlukas market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
10mg
20mg
Segment by Application
Antiasthmatic Agent
Anti-Inflammatory Agent
Leukotrien Receptor Antagonist
By Company
Astrazeneca
Par Pharm
Dr Reddys Labs
Medisure
Hamaz Pharma
Delta Pharma
Chiesi Farmaceutici
General Pharma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Market Analysis and Insights: Global Zafirlukas Market
Due to the COVID-19 pandemic, the global Zafirlukas market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 10mg accounting for % of the Zafirlukas global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Antiasthmatic Agent segment is altered to an % CAGR throughout this forecast period.
China Zafirlukas market size is valued at US$ million in 2021, while the US and Europe Zafirlukas are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Zafirlukas landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Zafirlukas include Astrazeneca, Par Pharm, Dr Reddys Labs, Medisure, Hamaz Pharma, Delta Pharma, Chiesi Farmaceutici and General Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Zafirlukas Scope and Segment
Zafirlukas market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Zafirlukas market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
10mg
20mg
Segment by Application
Antiasthmatic Agent
Anti-Inflammatory Agent
Leukotrien Receptor Antagonist
By Company
Astrazeneca
Par Pharm
Dr Reddys Labs
Medisure
Hamaz Pharma
Delta Pharma
Chiesi Farmaceutici
General Pharma
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
